entrectinib: Clinical Trials

22 trials of entrectinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 recruiting, 6 active not recruiting, 2 completed, 2 not yet recruiting. 22 Phase 2, 3 Phase 3, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 222Recruiting 8, Active not recruiting 6, Completed 2, Not yet recruiting 2, Terminated 2, Unknown 2
Phase 33Recruiting 2, Active not recruiting 1
Phase 12Active not recruiting 1, Terminated 1

Follow entrectinib: new trials by email Literature Review of entrectinib trials Research Report on entrectinib

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
Alectinib, Entrectinib, Surgery - Infant-Type Hemispheric Glioma
Phase 2Not yet recruitingSt. Jude Children's Research Hospital502026-11-012026-11-04
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Entrectinib, Cyclophosphamide, Etoposide - High Grade Glioma, CNS Tumor
Phase 2RecruitingSt. Jude Children's Research Hospital522026-05-012026-11-03
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
Entrectinib - Haematological Malignancy, Malignancy
Phase 2 / Phase 3RecruitingCancer Research UK302025-11-302025-11-24
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour
Phase 2Not yet recruitingPeking University Shenzhen Hospital2002025-01-012024-11-18
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour
Phase 2 / Phase 3RecruitingCancer Research UK8252023-03-012026-07-01
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor
Phase 2RecruitingHelsinki University Central Hospital2502021-12-102026-11-10
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Anlotinib, Lenvatinib, Sorafenib - Locally Advanced Thyroid Gland Carcinoma
Phase 2RecruitingWest China Hospital752021-06-012024-12-05
Improving Public Cancer Care by Implementing Precision Medicine in Norway
Atezolizumab - Cancer Metastatic
Phase 2RecruitingOslo University Hospital30002021-04-012024-02-29
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Entrectinib, Alectinib, Atezolizumab - Solid Tumors
Phase 2Active not recruitingHoffmann-La Roche9202021-01-182026-09-04
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
Entrectinib, Letrozole, Goserelin - Invasive Lobular Breast Carcinoma, ER+ Breast Cancer
Phase 2UnknownJules Bordet Institute652021-01-142024-12-04
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
Entrectinib, Inavolisib, Alectinib - Advanced Unresectable or Metastatic Solid Malignancy
Phase 2CompletedGenentech, Inc.2522021-01-132025-01-08
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
PAC-1, Entrectinib - Uveal Melanoma
Phase 1 / Phase 2TerminatedArkadiusz Z. Dudek, MD62021-01-112023-11-22
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Alectinib, Entrectinib, Vemurafenib - Non-small Cell Lung Cancer
Phase 2Active not recruitingGenentech, Inc.992020-11-062026-11-10
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer
Phase 2UnknownFondazione per la Medicina Personalizzata4002020-10-072023-10-03
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Osimertinib, Alectinib 150 MG, Crizotinib 250 MG - Non Small Cell Lung Cancer, EGFR Gene Mutation
Phase 2RecruitingHunan Province Tumor Hospital60002020-04-162024-10-22
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib - CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain
Phase 2Active not recruitingAlliance for Clinical Trials in Oncology502019-10-172026-10-30
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Alectinib, Vismodegib, Ipatasertib - Cancer of Unknown Primary Site
Phase 2CompletedHoffmann-La Roche5292018-07-102025-11-19
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Alectinib, Atezolizumab, Pemetrexed - Non-Small Cell Lung Cancer
Phase 2 / Phase 3Active not recruitingHoffmann-La Roche10002017-09-222026-09-03
The Drug Rediscovery Protocol (DRUP Trial)
Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors
Phase 2RecruitingThe Netherlands Cancer Institute15502016-08-012024-01-24
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Entrectinib - Solid Tumors, CNS Tumors
Phase 1 / Phase 2Active not recruitingHoffmann-La Roche692016-05-032026-09-23

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Brain Neoplasms (5)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Glioma (3)  ·  Hematologic Neoplasms (3)  ·  Melanoma (3)  ·  Neoplasm Metastasis (3)  ·  Neoplasms (3)  ·  Breast Neoplasms (2)  ·  Central Nervous System Neoplasms (2)  ·  Lymphoproliferative Disorders (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms by Site (2)  ·  Salivary Gland Neoplasms (2)  ·  Sarcoma (2)  ·  Thyroid Cancer, Papillary (2)

Sponsors

Hoffmann-La Roche (5)  ·  Cancer Research UK (2)  ·  Genentech, Inc. (2)  ·  St. Jude Children's Research Hospital (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Arkadiusz Z. Dudek, MD (1)  ·  Fondazione per la Medicina Personalizzata (1)  ·  Helsinki University Central Hospital (1)  ·  Hunan Province Tumor Hospital (1)  ·  Jules Bordet Institute (1)  ·  Oslo University Hospital (1)  ·  Peking University Shenzhen Hospital (1)  ·  The Netherlands Cancer Institute (1)  ·  University of California, San Francisco (1)  ·  West China Hospital (1)

Countries

United States (11)  ·  China (6)  ·  France (6)  ·  Italy (6)  ·  United Kingdom (6)  ·  Germany (5)  ·  Spain (5)  ·  Australia (4)  ·  Belgium (4)  ·  Brazil (4)  ·  Hong Kong (4)  ·  Japan (4)  ·  Poland (4)  ·  South Korea (4)  ·  Canada (3)

Top investigators

Matthew Krebs, Dr (2)  ·  Adil Daud (1)  ·  Aditi Bagchi, M.D., Ph.D. (1)  ·  Andrea Botticelli (1)  ·  Arkadiusz Dudek, MD, PhD (1)  ·  Daniel Moreira, MD, MEd (1)  ·  E.E. Voest, prof. (1)  ·  Katriina Jalkanen, MD, PhD (1)  ·  Paolo Marchetti (1)  ·  Philippe Aftimos, MD (1)  ·  Priscilla Brastianos, MD (1)  ·  Yongchang Zhang, MD (1)  ·  Zhihui Li, Professor (1)

Results publications

PMID 40086048, PMID 31838007, PMID 41213248, PMID 29118225, PMID 31838015, PMID 32479604, PMID 33646820, PMID 34427452, PMID 34924145, PMID 35086719, PMID 35119530, PMID 35395680, PMID 35568909, PMID 35598186, PMID 35695563, PMID 35995953, PMID 36870947, PMID 36924196, PMID 37424386, PMID 37738028, PMID 38190582, PMID 38630551, PMID 38848521, PMID 38898120, PMID 39096924, PMID 39549678, PMID 40304938, PMID 40341199, PMID 40525978, PMID 41023484, PMID 41392942, PMID 41963505, PMID 41986720, PMID 42691436

NIH funding

2017 (2), 2023 (2), 2015 (1), 2018 (1), U10CA180821 (1)